Future Pipeline

Future Pipeline

YARAL Pharma will initially focus on the commercialization of IBSA Pharma’s corporate pipeline of authorized generics in the areas of pain and endocrinology and will expand its offering of high-quality products across a range of therapeutic areas.

Product Portfolio

YARAL Pharma is poised to rapidly expand its product line through its internal pipeline as well as outside partnerships.

Our portfolio focus will include a mix of oral solid dosage (OSD), complex and 505(b)2 products in select therapeutic areas including

  • Pain and Inflammation 
  • Endocrinology
  • Reproductive Medicine
  • Rheumatology
  • Dermatology
  • Ophthalmology

Pain and Inflamation


Reproductive Medicine



Let us help

Contact Us
Scroll to Top